Sharon Brunecz - 17 Feb 2022 Form 4 Insider Report for AMEDISYS INC (AMED)

Reporting relationship: Chief Human Resources Officer
Issuer ticker: AMED
Reported as of: 17 Feb 2022
Net transaction value: -$163,923
SEC form: 4
Accepted by SEC: 22 Feb 2022, 20:05:50 UTC
Prior SEC filing: 29 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Jennifer R. Guckert, pursuant to a power of attorney

Key filing fact

Sharon Brunecz filed Form 4 for AMEDISYS INC (AMED) on 22 Feb 2022.

Key facts

This page summarizes Sharon Brunecz's Form 4 filing for AMEDISYS INC (AMED).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 22 Feb 2022, 20:05.

Change

Previous filing in this sequence was filed on 29 Jul 2021.
Current net transaction value: -$163,923.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMED transaction

Common Stock

Award

Transaction value: $0
Shares: +1,309
Change %: +5.1%
Price: $0.000000
Shares after: 27,094
Date: 17 Feb 2022
Ownership: Direct
Footnotes: F1

AMED transaction

Common Stock

Tax liability

Transaction value: $163,923
Shares: -1,162
Change %: -4.3%
Price: $141.07
Shares after: 25,932
Date: 20 Feb 2022
Ownership: Direct

AMED holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 117
Date: 17 Feb 2022
Ownership: Through 401(k) Plan
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMED transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +3,060
Change %
Price: $0.000000
Shares after: 3,060
Date: 17 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,060
Exercise price: $143.25
Footnotes: F3

AMED transaction Derivative

Restricted Stock Unit (Performance-Based Vesting)

Award

Transaction value: $0
Shares: +2,618
Change %
Price: $0.000000
Shares after: 2,618
Date: 17 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,618
Exercise price
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Issuer awarded the Reporting Person 1,309 time-based RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest in equal, 25% installments on each of February 20, 2023, 2024, 2025 and 2026, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the RSUs.

Footnote F2

The information in this report is based on a plan statement dated as of December 31, 2021.

Footnote F3

The Stock Options are subject to time-based vesting conditions and will vest in equal, 25% installments on each of February 20, 2023, 2024, 2025 and 2026, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options.

Footnote F4

The performance-based RSUs will vest based on certification of achievement of an identified performance measure for 2022, with additional time-based vesting in equal 25% installments on each of the certification date and February 20, 2024, 2025 and 2026, assuming the Reporting Person remains continuously employed on the vesting date. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved.